The reported pharmacokinetic study suggested that CYP2E1 was the most stable enzyme, whereas CYP2C19 (with CYP1A1 and CYP2D6 in the middle) was the most vulnerable in liver failure [1]. The gene discussed is CYP2D6; the disease is Hepatic failure.